Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -72.69% is 15% below its 5-year average of -63.36%, around the middle of its 5-year range (-146.06%–-11.07%).
45.88% below its 12-month average of -49.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.84%.
RETURN ON ASSETS (ROA)
-72.69%
RETURN ON ASSETS (ROA) AVG TTM
-49.83%
RETURN ON ASSETS (ROA) AVG 3Y
-64.20%
RETURN ON ASSETS (ROA) AVG 5Y
-63.36%
RETURN ON ASSETS (ROA) AVG 10Y
-60.75%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-45.88%
CURRENT VS 3Y AVG
-13.23%
CURRENT VS 5Y AVG
-14.72%
CURRENT VS 10Y AVG
-19.65%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-125.47%
vs the sector median at left
Exicure, Inc.
Market Cap
$6.88M
Return on Assets (ROA)
-72.69%
TTM Avg
-49.83%
3Y Avg
-64.20%
5Y Avg
-63.36%
Market Cap
$6.74M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$7.04M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$7.07M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$7.12M
Return on Assets (ROA)
-457.62%
TTM Avg
-117.02%
3Y Avg
-190.78%
5Y Avg
-182.53%
Market Cap
$7.15M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
Market Cap
$6.61M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$6.60M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$6.60M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.88M | -72.69% | -49.83% | -64.20% | -63.36% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -71.23% | -61.08% | -51.04% | -61.11% |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -95.26% | -176.86% | -120.19% | -105.02% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -206.32% | -53.14% | -33.03% | -33.03% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | -457.62% | -117.02% | -190.78% | -182.53% |
| Longeveron Inc. (LGVN)vs › | $7.15M | -151.57% | -141.88% | -132.44% | -101.65% |
| Biomerica, Inc. (BMRA)vs › | $6.61M | -55.85% | -69.75% | -63.38% | -59.39% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | -426.88% | -139.62% | -270.47% | -207.15% |
| Aclarion, Inc. (ACON)vs › | $6.60M | -50.98% | -191.11% | -206.10% | -240.87% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | -97.60% | -274.34% | -160.93% | -165.76% |
ROA
-72.7%
ROE
-847.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.23% |
| 2024-12-31 | -64.43% |
| 2023-12-31 | -146.06% |
| 2022-12-31 | -11.07% |
| 2021-12-31 | -98.82% |
| 2020-12-31 | -24.56% |
| 2019-12-31 | -22.82% |
| 2018-12-31 | -77.94% |
| 2017-12-31 | -37.99% |
| 2016-12-31 | -82.33% |
| 2015-12-31 | -67.03% |
